Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy
ObjectiveThe treatment of residual/recurrent cervical cancer within a previously irradiated area is challenging and generally associated with a poor outcome. Local treatments such as salvage surgery and re-irradiation are usually traumatic and have limited efficacy. High intensity focused ultrasound...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.995930/full |
| _version_ | 1828142385145577472 |
|---|---|
| author | Qin Zhong Fei Tang Tingting Ni Yanping Chen Yuncong Liu Jing Wu Wen Zhou Zhiyu Feng Xiaokai Lu Shisheng Tan Yu Zhang Yu Zhang |
| author_facet | Qin Zhong Fei Tang Tingting Ni Yanping Chen Yuncong Liu Jing Wu Wen Zhou Zhiyu Feng Xiaokai Lu Shisheng Tan Yu Zhang Yu Zhang |
| author_sort | Qin Zhong |
| collection | DOAJ |
| description | ObjectiveThe treatment of residual/recurrent cervical cancer within a previously irradiated area is challenging and generally associated with a poor outcome. Local treatments such as salvage surgery and re-irradiation are usually traumatic and have limited efficacy. High intensity focused ultrasound (HIFU) treatment can directly ablate solid tumors without damaging neighboring healthy tissue. However, the HIFU studies for these patients are limited. Experience gained over the course of 10 years with the use of HIFU for the management of residual/recurrent cervical cancer after chemoradiotherapy is reported herein.Methods153 patients with residual/recurrent cervical cancer in a previously irradiated field who received HIFU treatment between 2010 and 2021 were retrospectively analyzed. Adverse effects, survival benefit and factors affecting prognosis were given particular attention.ResultsA total of 36 patients (23.5%) achieved a partial response following HIFU treatment and 107 patients (69.9%) had stable disease. The objective response and disease control rates were 23.5% and 93.5%, respectively. The median progression-free survival (mPFS) and median overall survival (mOS) were 17.0 months and 24.5 months, respectively. Moreover, patients with lesions ≥1.40 cm before HIFU treatment and a shrinkage rate ≥ 30% after treatment had a higher mPFS and mOS, and patients with lesions ≤1.00 cm after HIFU treatment had a higher mPFS (P=<0.05). All the treatment-related adverse events were limited to minor complications, which included skin burns, abdominal pain and vaginal discharge.ConclusionsHIFU treatment is likely a preferred option for cervical cancer patients with residual disease or recurrence following CRT that can safely improve the local control rate and extend survival. |
| first_indexed | 2024-04-11T19:39:36Z |
| format | Article |
| id | doaj.art-9197c96c029e42f3a91b301e91e27ce5 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T19:39:36Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-9197c96c029e42f3a91b301e91e27ce52022-12-22T04:06:44ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-10-011310.3389/fimmu.2022.995930995930Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapyQin Zhong0Fei Tang1Tingting Ni2Yanping Chen3Yuncong Liu4Jing Wu5Wen Zhou6Zhiyu Feng7Xiaokai Lu8Shisheng Tan9Yu Zhang10Yu Zhang11Department of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaDepartment of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaDepartment of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaDepartment of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaDepartment of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaDepartment of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaDepartment of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaDepartment of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaDepartment of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaDepartment of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaDepartment of Medical Oncology, Guizhou Province People’s Hospital, Guiyang, ChinaNational Health Commission Key Laboratory of Pulmonary Immune-Related Diseases, Guizhou Province People's Hospital, Guiyang, Guizhou, ChinaObjectiveThe treatment of residual/recurrent cervical cancer within a previously irradiated area is challenging and generally associated with a poor outcome. Local treatments such as salvage surgery and re-irradiation are usually traumatic and have limited efficacy. High intensity focused ultrasound (HIFU) treatment can directly ablate solid tumors without damaging neighboring healthy tissue. However, the HIFU studies for these patients are limited. Experience gained over the course of 10 years with the use of HIFU for the management of residual/recurrent cervical cancer after chemoradiotherapy is reported herein.Methods153 patients with residual/recurrent cervical cancer in a previously irradiated field who received HIFU treatment between 2010 and 2021 were retrospectively analyzed. Adverse effects, survival benefit and factors affecting prognosis were given particular attention.ResultsA total of 36 patients (23.5%) achieved a partial response following HIFU treatment and 107 patients (69.9%) had stable disease. The objective response and disease control rates were 23.5% and 93.5%, respectively. The median progression-free survival (mPFS) and median overall survival (mOS) were 17.0 months and 24.5 months, respectively. Moreover, patients with lesions ≥1.40 cm before HIFU treatment and a shrinkage rate ≥ 30% after treatment had a higher mPFS and mOS, and patients with lesions ≤1.00 cm after HIFU treatment had a higher mPFS (P=<0.05). All the treatment-related adverse events were limited to minor complications, which included skin burns, abdominal pain and vaginal discharge.ConclusionsHIFU treatment is likely a preferred option for cervical cancer patients with residual disease or recurrence following CRT that can safely improve the local control rate and extend survival.https://www.frontiersin.org/articles/10.3389/fimmu.2022.995930/fullhigh-intensity focused ultrasoundcervical cancerablationresidual diseasesneoplasm recurrence |
| spellingShingle | Qin Zhong Fei Tang Tingting Ni Yanping Chen Yuncong Liu Jing Wu Wen Zhou Zhiyu Feng Xiaokai Lu Shisheng Tan Yu Zhang Yu Zhang Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy Frontiers in Immunology high-intensity focused ultrasound cervical cancer ablation residual diseases neoplasm recurrence |
| title | Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy |
| title_full | Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy |
| title_fullStr | Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy |
| title_full_unstemmed | Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy |
| title_short | Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy |
| title_sort | salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy |
| topic | high-intensity focused ultrasound cervical cancer ablation residual diseases neoplasm recurrence |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.995930/full |
| work_keys_str_mv | AT qinzhong salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT feitang salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT tingtingni salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT yanpingchen salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT yuncongliu salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT jingwu salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT wenzhou salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT zhiyufeng salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT xiaokailu salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT shishengtan salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT yuzhang salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy AT yuzhang salvagehighintensityfocusedultrasoundforresidualorrecurrentcervicalcancerafterdefinitivechemoradiotherapy |